Akeso’s data look impressive, but perhaps not impressive enough to sustain Summit’s valuation.

The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.

Belrestotug’s lung cancer trial features among the ESMO late-breakers, as do Immutep, Scorpion and others.

Second time lucky for Zynyz, Amgen’s PRMT5 comeback, and other possible surprises.

After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.

ASP3082 grabs some early attention among degraders set to feature at ESMO.

The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.

Early attention falls on ADCs originated by ProfoundBio, SystImmune, MediLink and Seagen.